Tacrolimus sustained-release capsule project

The total investment of the project is 27.86 million yuan. The project starts and ends from October 2020 to December 2023. The number of project teams is 15. The main business areas are high-end pharmaceutical preparations, core technology, oral sustained-release intention. The country is the United States, and the intention unit is LATITUDePharmaceuticals Inc (LATITUDE Pharmaceutical Company), located in California, USA. Currently, in the domestic immunosuppressive market, tacrolimus has the largest sales volume, but its treatment index (NTI) is narrow, and the blood drug concentration must be stable within a certain level. Excessive concentration will increase the risk of toxic reactions, while insufficient concentration will increase rejection reactions. Tacrolimus sustained-release capsules are the sustained-release dosage form of tacrolimus, and the changes in dosage form make the blood concentration of tacrolimus more stable and can reduce the coefficient of variation of blood concentration, which has clinical medication advantages. Huabei Pharmaceutical has high-quality raw materials of tacrolimus, which can fully meet the research and development and subsequent industrial production of this product. It also has synergistic drugs in the field of immunosuppressants. After successful research and development, the market advantage is obvious.